Published in Blood Coagul Fibrinolysis on April 01, 1998
Three novel beta-propeller mutations causing Glanzmann thrombasthenia result in production of normally stable pro-alphaIIb, but variably impaired progression of pro-alphaIIbbeta3 from endoplasmic reticulum to Golgi. J Thromb Haemost (2005) 0.91
A 13-bp deletion in alpha(IIb) gene is a founder mutation that predominates in Palestinian-Arab patients with Glanzmann thrombasthenia. J Thromb Haemost (2005) 0.86
Ordered rearrangement of immunoglobulin heavy chain variable region segments. EMBO J (1984) 6.67
Identification of an Abelson murine leukemia virus-encoded protein present in transformed fibroblast and lymphoid cells. Proc Natl Acad Sci U S A (1978) 6.38
Organization and reorganization of immunoglobulin genes in A-MULV-transformed cells: rearrangement of heavy but not light chain genes. Cell (1981) 6.31
von Willebrand factor-cleaving protease in thrombotic thrombocytopenic purpura and the hemolytic-uremic syndrome. N Engl J Med (1998) 6.17
Evidence for cross-bridge attachment in relaxed muscle at low ionic strength. Proc Natl Acad Sci U S A (1982) 5.38
Analysis of prothrombotic and vascular risk factors in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology (1999) 5.34
A quantitative assay for transformation of bone marrow cells by Abelson murine leukemia virus. J Exp Med (1976) 5.13
Rearrangement of antigen receptor genes is defective in mice with severe combined immune deficiency. Cell (1986) 4.68
The defect in murine severe combined immune deficiency: joining of signal sequences but not coding segments in V(D)J recombination. Cell (1988) 4.34
Multiple immunoglobulin heavy-chain gene transcripts in Abelson murine leukemia virus-transformed lymphoid cell lines. Mol Cell Biol (1982) 4.26
Rate of force generation in muscle: correlation with actomyosin ATPase activity in solution. Proc Natl Acad Sci U S A (1986) 4.13
Continuing kappa-gene rearrangement in a cell line transformed by Abelson murine leukemia virus. Cell (1982) 3.86
In vitro transformation of lymphoid cells by Abelson murine leukemia virus. Proc Natl Acad Sci U S A (1975) 3.47
Technique for stabilizing the striation pattern in maximally calcium-activated skinned rabbit psoas fibers. Biophys J (1983) 3.33
The effect of helper virus on Abelson virus-induced transformation of lymphoid cells. J Exp Med (1978) 3.25
EFNS guidelines on the use of skin biopsy in the diagnosis of peripheral neuropathy. Eur J Neurol (2005) 3.17
Immunoglobulin heavy-chain expression and class switching in a murine leukaemia cell line. Nature (1982) 3.05
Intramuscular versus oral antibiotic therapy for the prevention of meningitis and other bacterial sequelae in young, febrile children at risk for occult bacteremia. J Pediatr (1994) 2.79
X-ray diffraction evidence for cross-bridge formation in relaxed muscle fibers at various ionic strengths. Biophys J (1984) 2.73
Secondary genomic rearrangement events in pre-B cells: VHDJH replacement by a LINE-1 sequence and directed class switching. EMBO J (1986) 2.62
Concerted deletions and inversions are caused by mitotic recombination between delta sequences in Saccharomyces cerevisiae. Mol Cell Biol (1987) 2.56
Sequences of the A-MuLV protein needed for fibroblast and lymphoid cell transformation. Cell (1983) 2.54
Preparation of syngeneic tumor regressor serum reactive with the unique determinants of the Abelson murine leukemia virus-encoded P120 protein at the cell surface. J Virol (1979) 2.50
Recombinant activated factor VII in treatment of bleeding complications following hematopoietic stem cell transplantation. J Thromb Haemost (2005) 2.46
Coexistence of hereditary homocystinuria and factor V Leiden--effect on thrombosis. N Engl J Med (1996) 2.38
Induction of a chronic myelogenous leukemia-like syndrome in mice with v-abl and BCR/ABL. Proc Natl Acad Sci U S A (1990) 2.36
Mutations in the ER-Golgi intermediate compartment protein ERGIC-53 cause combined deficiency of coagulation factors V and VIII. Cell (1998) 2.34
Homozygous protein C deficiency manifested by massive venous thrombosis in the newborn. N Engl J Med (1984) 2.26
International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost (2013) 2.24
Comparison of dosage schedules of rt-PA in the treatment of proximal deep vein thrombosis. J Lab Clin Med (1992) 2.22
A transformation-defective mutant of Abelson murine leukemia virus lacks protein kinase activity. Proc Natl Acad Sci U S A (1980) 2.16
Abelson murine leukemia virus mutants with alterations in the virus-specific P120 molecule. J Virol (1980) 2.16
False-positive tests for heparin-induced thrombocytopenia in patients with antiphospholipid syndrome and systemic lupus erythematosus. J Thromb Haemost (2009) 2.14
Did Jesus Christ die of pulmonary embolism? J Thromb Haemost (2005) 2.04
Inherited thrombophilia: Part 1. Thromb Haemost (1996) 2.00
Only site-directed antibodies reactive with the highly conserved src-homologous region of the v-abl protein neutralize kinase activity. J Virol (1984) 1.93
The cross-bridge cycle in muscle. Mechanical, biochemical, and structural studies on single skinned rabbit psoas fibers to characterize cross-bridge kinetics in muscle for correlation with the actomyosin-ATPase in solution. Basic Res Cardiol (1986) 1.92
Stiffness of skinned rabbit psoas fibers in MgATP and MgPPi solution. Biophys J (1986) 1.91
Structures of actomyosin crossbridges in relaxed and rigor muscle fibers. Biophys J (1989) 1.91
Cross-bridge attachment in relaxed muscle. Adv Exp Med Biol (1984) 1.89
SAM2 encodes the second methionine S-adenosyl transferase in Saccharomyces cerevisiae: physiology and regulation of both enzymes. Mol Cell Biol (1988) 1.87
An active v-abl protein tyrosine kinase blocks immunoglobulin light-chain gene rearrangement. Genes Dev (1994) 1.85
Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. J Thromb Haemost (2008) 1.81
Genome structure of Abelson murine leukemia virus variants: proviruses in fibroblasts and lymphoid cells. J Virol (1981) 1.73
p19(Arf) induces p53-dependent apoptosis during abelson virus-mediated pre-B cell transformation. Proc Natl Acad Sci U S A (1998) 1.73
Tyrosine kinase oncogenes abrogate interleukin-3 dependence of murine myeloid cells through signaling pathways involving c-myc: conditional regulation of c-myc transcription by temperature-sensitive v-abl. Mol Cell Biol (1989) 1.64
Single-molecule tracking of myosins with genetically engineered amplifier domains. Nat Struct Biol (2001) 1.58
Transformation of immature lymphoid cells by Abelson murine leukemia virus. Immunol Rev (1979) 1.58
Factor XI deficiency in Ashkenazi Jews in Israel. N Engl J Med (1991) 1.56
Equatorial x-ray diffraction from single skinned rabbit psoas fibers at various degrees of activation. Changes in intensities and lattice spacing. Biophys J (1985) 1.54
Role of aspirin in reducing the frequency of second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. Eye (Lond) (1999) 1.54
Trauma in infants less than three months of age. Pediatr Emerg Care (1993) 1.50
Abelson leukemia virus induces lymphoid and erythroid colonies in infected fetal cell cultures. Cell (1981) 1.50
Acidic sphingomyelinase mediates entry of N. gonorrhoeae into nonphagocytic cells. Cell (1997) 1.47
Point mutations regarded as missense mutations cause splicing defects in the factor XI gene. J Thromb Haemost (2011) 1.46
Heparanase neutralizes the anticoagulation properties of heparin and low-molecular-weight heparin. J Thromb Haemost (2006) 1.44
Leukemogenicity of clonal isolates of murine leukemia viruses. J Natl Cancer Inst (1978) 1.44
Use of dexamethasone in the outpatient management of acute laryngotracheitis. Pediatrics (1995) 1.43
Successful use of recombinant activated factor VII (Novoseven) in controlling severe intra-abdominal bleeding after liver needle biopsy. Thromb Haemost (2002) 1.40
The role of angiotensin converting enzyme and angiotensin II type 1 receptor gene polymorphisms in patients with nonarteritic anterior ischemic optic neuropathy. Ophthalmology (2000) 1.40
Diagnosis of femoropopliteal venous thrombosis with MR imaging: a comparison of four MR pulse sequences. AJR Am J Roentgenol (1990) 1.39
In vivo tyrosine phosphorylations of the Abelson virus transforming protein are absent in its normal cellular homolog. Cell (1982) 1.39
Mechanical and structural approaches to correlation of cross-bridge action in muscle with actomyosin ATPase in solution. Annu Rev Physiol (1987) 1.39
Thrombocytopenia associated with low-molecular-weight heparin. Lancet (1991) 1.39
Age estimates of two common mutations causing factor XI deficiency: recent genetic drift is not necessary for elevated disease incidence among Ashkenazi Jews. Am J Hum Genet (1999) 1.38
Interferon-alpha-2b with VMCP for induction in multiple myeloma: the Israel Myeloma Cooperative Group experience. Isr J Med Sci (1995) 1.38
Treatment of male infertility: the ICSI revolution is secure. N Z Med J (1996) 1.38
Abelson virus-transformed lymphocytes: null cells that modulate H-2. Cell (1977) 1.37
Transcriptional activation of a ras-like gene (kir) by oncogenic tyrosine kinases. Proc Natl Acad Sci U S A (1994) 1.37
Ca2+-sensitive cross-bridge dissociation in the presence of magnesium pyrophosphate in skinned rabbit psoas fibers. Biophys J (1986) 1.36
Inherited thrombophilia: Part 2. Thromb Haemost (1996) 1.34
Cardiac valvular vegetations in cancer patients: a prospective echocardiographic study of 200 patients. Am J Med (1997) 1.32
Prophylactic therapy with enoxaparin during L-asparaginase treatment in children with acute lymphoblastic leukemia. Blood Coagul Fibrinolysis (2001) 1.31
Safety of low-molecular-weight heparin in pregnancy: a systematic review. Thromb Haemost (1999) 1.31
Clinical and laboratory aspects of disseminated intravascular coagulation (DIC): a study of 118 cases. Thromb Haemost (1978) 1.30
Mapping cell surface antigens on mouse pre-B cell lines. Eur J Immunol (1985) 1.29
Protein stabilization explains the gag requirement for transformation of lymphoid cells by Abelson murine leukemia virus. J Virol (1985) 1.29
Cardiomyopathy mutations reveal variable region of myosin converter as major element of cross-bridge compliance. Biophys J (2009) 1.28
Platelet vitronectin receptor expression differentiates Iraqi-Jewish from Arab patients with Glanzmann thrombasthenia in Israel. Blood (1991) 1.28
Effect of Ca2+ on weak cross-bridge interaction with actin in the presence of adenosine 5'-[gamma-thio]triphosphate). Proc Natl Acad Sci U S A (1992) 1.27
Inherited platelet disorders. Haemophilia (2012) 1.27
Calcium activation and maximum unloaded shortening velocity. Investigation on glycerinated skeletal and heart muscle preparations. Basic Res Cardiol (1980) 1.26
The v-abl tyrosine kinase negatively regulates NF-kappa B/Rel factors and blocks kappa gene transcription in pre-B lymphocytes. Genes Dev (1994) 1.24
International clinical practice guidelines for the treatment and prophylaxis of thrombosis associated with central venous catheters in patients with cancer. J Thromb Haemost (2013) 1.21
Monoclonal antibodies specific for v-abl- and c-abl-encoded molecules. J Virol (1986) 1.21
Heparanase induces tissue factor expression in vascular endothelial and cancer cells. J Thromb Haemost (2006) 1.21
Clinical and socio-professional fate of isocyanate-induced asthma. Clin Allergy (1987) 1.20
Factor V Leiden and antiphospholipid antibodies are significant risk factors for ischemic stroke in children. Stroke (2000) 1.20
Increased risk of cancer in patients with Gaucher disease. Cancer (1993) 1.20
Psychological distress among male patients and male spouses: what do oncologists need to know? Ann Oncol (2009) 1.19
Persistent asthma after inhalation of a mixture of sodium hypochlorite and hydrochloric acid. Chest (1994) 1.18